

10 November 2016

### **Results Published Recommending Use of FerriScan® R2-MRI in Sickle Cell Disease**

Resonance Health (ASX: RHT) is pleased to announce further endorsement by the clinical community on the use of FerriScan R2-MRI for the management of patients with Sickle Cell Disease (SCD). The Company is pro-actively working with established and new FerriScan providers to increase use of FerriScan in the USA in key regions with high SCD prevalence. This evidence will assist the momentum of the campaign and strengthens the case for future reimbursement of the test. With clinical evidence increasing the Company will obtain expert advice regarding a renewed CPT code application for reimbursement in the USA.

Sickle Cell Disease affects over 100,000 people in the USA alone. Up to 15% of patients with SCD receive regular blood transfusions as part of their treatment, resulting in iron overload. As such, these patients require quantitative liver iron concentration monitoring, for which FerriScan R2-MRI is considered the global gold-standard.

The paper by the highly respected Dr Janet Kwiatkowski team at the Children's Hospital of Philadelphia, USA, has been published in the peer-reviewed Journal of Paediatric Oncology. The paper reports that the use of FerriScan benefited the management of Sickle Cell patients receiving transfusions, resulting in a reduced liver iron burden for patients at risk. The conclusion is that routine use of FerriScan R2-MRI for patients with SCD receiving regular blood transfusions is recommended. The publication has now been granted Open Access status which enables barrier-free dissemination among the scientific and clinical community.

The new publication can now be accessed online: [Transfusional Iron Overload in a Cohort of Children with Sickle Cell Disease: Impact of Magnetic Resonance Imaging, Transfusion Method, and Chelation.](#)

Sheila Murphy, Global Consultant for Resonance Health, USA, commented:

*"Having the strong support of key opinion leaders such as Dr Kwiatkowski, alongside new evidence on the impact of using FerriScan provided in this paper, is critical to winning long-term access to FerriScan for many more patients in the US. We are working closely with the clinical community and patient advocacy groups to lobby for access to FerriScan and are seeing a good response to our educational programs. The US is now our fastest growing market with a 25% increase in referrals over the last financial year and new hospitals being set up with FerriScan."*

Resonance Health recently attended the national Sickle Cell Disease Association of America (SCDAA) conference in the US, a prestigious annual event where the Company's Hospital Specialist, Pat Corley, received a special award for her contribution to the Sickle Cell Disease community. In London the Company also had a prominent presence at the international ASCAT Sickle Cell and Thalassaemia

conference in October, attended by over 100 delegates, which provided opportunity to promote awareness of the new publication. Resonance Health will continue to promote the use of FerriScan in the SCD community.

**For further information please contact:**

Sander Bangma  
General Manager, Resonance Health  
E: [SanderB@resonancehealth.com](mailto:SanderB@resonancehealth.com) P: +61 (0)8 9286 5300